Our vision is to “deliver affinity ligands based on either DNA, peptides or mixed mode to your targets in less than a week”. We intend to establish a great impact on development speed in therapeutics, diagnostis and separation of biomolecules creating biomarkers in a couple of days. A4 has started an internal program for making custom purfication “resins”. However the company will support anyone in the field of separations with product and business development. We believe that creating strong networks will increase our value to customers and accelerate the realization of our vision.

Jacques Clemens B.Sc., owner of A4 combines practical experiences in R&D (immunology) and international sales+management of bio-separation solutions. He worked as sales director for Amersham Pharmacia Biotech (GE Healthcare) and Pall Lifesciences and as vice president for Asahi Kasei Bioprocess selling chromatography, filtration and virus removal applications plus engineering solutions for the same. Most of these projects were highly customised, differing significantly for each client. Jacques founded A4 in 2013 to explore the potential of aptamers replacing antibodies and has built a solid network to deliver affinity products for various purposes.